The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia

Neurochemistry International

Volumn 52, Issue 6, 2008, Pages 1052-1060

  Engelborghs, Sebastiaan ^a,b,c,d   Vloeberghs, Ellen ^b   Le Bastard, Nathalie ^b   Van Buggenhout, Michael ^b,c,d   Mariën, Peter ^a,f   Somers, Nore ^a   Nagels, Guy ^a,b,e   Pickut, Barbara A ^a   De Deyn, Peter P ^a,b,d  

^a MIDDELHEIM HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d University College   (Belgium)

^e National Multiple Sclerosis Center   (Belgium)

^f FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

Aggression; Agitation; Behavior; BPSD; Cerebrospinal fluid; Dementia; Dopamine; Frontotemporal

Indexed keywords

ADRENALIN; DOPAMINE; NORADRENALIN; SEROTONIN;

ADULT; AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CAREGIVER BURDEN; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; ELECTROCHEMICAL DETECTION; FEMALE; FRONTOTEMPORAL DEMENTIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MIXED DEPRESSION AND DEMENTIA; NEUROPSYCHOLOGICAL TEST; NEUROTRANSMISSION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; AGGRESSION; ALZHEIMER DISEASE; BRAIN; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEMENTIA; DOPAMINE; EPINEPHRINE; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MENTAL DISORDERS; NEUROPSYCHOLOGICAL TESTS; NOREPINEPHRINE; PROSPECTIVE STUDIES; PSYCHOMOTOR AGITATION; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 40949158078     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2007.10.018     Document Type: Article

References (52)

1. Agren H., Mefford I.N., Rudorfer M.V., Linnoila M., and Potter W.Z. Interacting neurotransmitter systems: a non-experimental approach to the 5HIAA-HVA correlation in human CSF. J. Psychiatr. Res. 20 (1986) 175-193
2. Alexopoulos G.S., Abrams R.C., Young R.C., and Shamoian C.A. Cornell Scale for Depression in Dementia. Biol. Psychiatry 23 (1988) 271-284
3. American Psychiatric Association. DSM-IV: Diagnostic And Statistical Manual of Mental Disorders. fourth ed. (1994), American Psychiatric Association, Washington, DC
4. Blennow K., Wallin A., Gottfries C.G., Lekman A., Karlsson I., Skoog I., and Svennerholm L. Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. Neurobiol. Aging 13 (1991) 107-113
5. Chia L.-G., Cheng F.-C., and Kuo J.-S. Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease. J. Neurol. Sci. 116 (1993) 125-134
6. Cohen-Mansfield J., Marx M.S., and Rosenthal A.S. A description of agitation in a nursing home. J. Gerontol. 44 (1989) M77-M84
7. Cummings J.L. Frontal-subcortical circuits and human behavior. Arch. Neurol. 50 (1993) 873-880
8. De Deyn P.P., Engelborghs S., Saerens J., Goeman J., Mariën P., Maertens K., Nagels G., Martin J.-J., and Pickut B.A. The Middelheim Frontality Score: a behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer's disease. Int. J. Geriatr. Psychiatry 20 (2005) 70-79
9. Demonet J.F., Doyon B., Ousset P.J., Puel M., Mahagne M.H., Cardebat D., Duchein C., Viala M.F., Agniel A., Vellas B., and Rascol A. Standardization of a modular and hierarchic cognitive evaluation scale applicable to dementia. A French version of the Hierarchic Dementia Scale. Revue Neurologique 146 (1990) 490-501
10. Eldrup E., Mogensen P., Jacobsen J., Pakkenberg H., and Christensen N.J. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), and epinephrine in Parkinson's disease. Acta Neurol. Scand. 92 (1995) 116-121
11. Engelborghs S., Vloeberghs E., Maertens K., Marescau B., and De Deyn P.P. Evidence for an association between the CSF HVA:5-HIAA ratio and aggressiveness in patients with frontotemporal dementia but not in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75 (2004) 1080 (letter)
12. Engelborghs S., Dermaut B., Mariën P., Symons A., Vloeberghs E., Maertens K., Somers N., Goeman J., Rademakers R., Van den Broeck M., Pickut B., Cruts M., Van Broeckhoven C., and De Deyn P.P. Dose dependent effect of APOE ε4 on behavioral symptoms in frontal lobe dementia patients. Neurobiol. Aging 27 (2006) 285-292
13. Engelborghs S., De Vreese K., Van de Casteele T., Vanderstichele H., Van Everbroeck B., Cras P., Martin J.-J., Vanmechelen E., and De Deyn P.P. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol. Aging (2007) 10.1016/j.neurobiolaging.2007.02.016
14. Folstein M., Folstein S., and McHugh P.R. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-196
15. Franceschi M., Anchisi D., Pelati O., Zuffi M., Matarrese M., Moresco R.M., Fazio F., and Perani D. Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. Ann. Neurol. 57 (2005) 216-225
16. Francis P.T., Holmes C., Webster M.T., Stratman G.C., Procter A.W., and Bowen D.M. Preliminary neurochemical findings in non-Alzheimer dementia due to lobar atrophy. Dementia 4 (1993) 172-177
17. Garcia-Alloza M., Gil-Bea F.J., Diez-Ariza M., Chen C.P.L.-H., Francis P.T., Lasheras B., and Ramirez M.J. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 43 (2005) 442-449
18. Geracioti T.D., Keck P.E., Ekhator N.N., West S.A., Baker D.G., Hill K.K., Bruce A.B., and Wortman M.D. Continuous covariability of dopamine and serotonin metabolites in human cerebrospinal fluid. Biol. Psychiatry 44 (1998) 228-233
19. Herrmann N., Lactôt K.L., and Khan L.R. The role of norepinephrine in the behavioral and psychological symptoms of dementia. J. Neuropsychiatry Clin. Neurosci. 16 (2004) 261-276
20. Huey E.D., Putnam K.T., and Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 66 (2006) 17-22
21. Jenner P., Sheehy M., and Marsden C.D. Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease. Br. J. Clin. Pharmacol. 15 (1983) 277S-289S
22. Jibson M., Faull K.F., and Csernansky J.G. Intercorrelations among monoamine metabolite concentrations in human lumbar CSF are not due to a shared acid transport system. Biol. Psychiatry 28 (1990) 595-602
23. Kahn R.S., Davidson M., Knott P., Stern R.G., Apter S., and Davis K.L. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Arch. Gen. Psychiatry 50 (1993) 599-605
24. Kaplan E., Goodglass H., and Weintraub S. The Boston Naming Test (1983), Lea & Febiger, Philadelphia
25. Kelland M.D., Freeman A.S., and Chiodo L.A. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J. Pharmacol. Exp. Ther. 253 (1990) 803-811
26. Koyama E., Minegishi A., and Ishizaki T. Simultaneous determination of four monoamine metabolites and serotonin in cerebrospinal fluid by "high-performance" liquid chromatography with electrochemical detection; applications for patients with Alzheimer's disease. Clin. Chem. 34 (1988) 680-684
27. Lanari A., Amenta F., Silvestrelli G., Tomassoni D., and Parnetti L. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mech. Ageing Dev. 127 (2006) 158-165
28. Landes A.M., Sperry S.D., Strauss M.E., and Geldmacher D.S. Apathy in Alzheimer's disease. J. Am. Geriatr. Soc. 49 (2001) 1700-1707
29. Lowy M.T., and Meltzer H.Y. Stimulation of serum cortisol and prolactin secretion in humans by MK-212, a centrally active serotonin agonist. Biol. Psychiatry 23 (1988) 818-828
30. Mann D.M.A., South P.W., Snowden J.S., and Neary D. Dementia of the frontal lobe type: neuropathology and immunohistochemistry. J. Neurol. Neurosurg. Psychiatry 56 (1993) 605-614
31. Mariën P., Mampaey E., Vervaet A., Saerens J., and De Deyn P.P. Normative data for the Boston Naming Test in native Dutch-speaking Belgian elderly. Brain Lang. 65 (1998) 447-467
32. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34 (1984) 939-944
33. Mega M.S., and Cummings J.L. Frontal-subcortical circuits and neuropsychiatric disorders. J. Neuropsychiatry Clin. Neurosci. 6 (1994) 358-370
34. Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., and Benson D.F. Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria. Neurology 51 (1998) 1546-2154
35. Pickut B.A., Saerens J., Mariën P., Borggreve F., Goeman J., Vandevivere J., Vervaet A., Dierckx R., and De Deyn P.P. Discriminative use of SPECT in frontal lobe-type dementia versus (senile) dementia of the Alzheimer's type. J. Nucl. Med. 38 (1997) 929-934
36. Procter A.W., Qurne M., and Francis P.T. Neurochemical features of frontotemporal dementia. Dement. Geriatr. Cogn. Disorders 10 Suppl. 1 (1999) 80-84
37. Raskind M.A., Peskind E.R., Holmes C., and Goldstein D.S. Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Biol. Psychiatry 46 (1999) 756-765
38. Reisberg B., Ferris S.H., de Leon M.J., and Crook T. The Global Deterioration Scale (GDS) for assessment of primary degenerative dementia. Am. J. Psychiatry 139 (1982) 1136-1139
39. Reisberg B., Borenstein J., Salob S.P., Ferris S.H., Franssen E., and Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J. Clin. Psychiatry 48 Suppl. 5 (1987) 9-15
40. Rinne J.O., Laine M., Kaasinen V., Norvasuo-Heila M.K., Nagren K., and Helenius H. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology 58 (2002) 1489-1493
41. Román G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., Amaducci L., Orgogozo J.M., Brun A., Hofman A., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43 (1993) 250-260
42. Sjögren M., Minthon L., Passant U., Blennow K., and Wallin A. Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. Neurobiol. Aging 19 (1998) 379-384
43. Sjögren M., Wikkelso C., Ostling S., Wallin A., and Blennow K. Biological correlates of clinical subgroups of Alzheimer's disease. Dement. Geriatr. Cogn. Disorders 14 (2002) 191-197
44. Soderstrom H., Blennow K., Manhem A., and Forsman A. CSF studies in violent offenders. I. 5-HIAA as a negative and HVA as a positive predictor of psychopathy. J. Neural Trans. 108 (2001) 869-878
45. Soderstrom H., Blennow K., Sjodin A.-K., and Forsman A. New evidence for an association between the CSF HVA:5-HIAA ratio and psychopathic traits. J. Neurol. Neurosurg. Psychiatry 74 (2003) 918-921
46. Sourkes T.L. On the origin of homovanillic acid (HVA) in the cerebrospinal fluid. J. Neural Trans. 34 (1973) 153-157
47. Sparks D.L., and Markesbery W.R. Altered serotonergic and cholinergic synaptic markers in Pick's disease. Arch. Neurol. 48 (1991) 796-799
48. Szot P., White S.S., Greenup L., Leverenz J.B., Peskind E.R., and Raskind M.A. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J. Neurosci. 26 (2006) 467-478
49. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., Salmon D.P., Lowe J., Mirra S.S., Byrna E.J., Lennox G., Quinn N.P., Edwardson J.A., Ince P.G., Bergeron C., Burns A., Miller B.L., Lovestone S., Collerton D., Jansen E.N.H., Ballard C., de Vos R.A.I., Wilcock G.K., Jellinger K.A., Perry R.H., and for the Consortium on Dementia with Lewy Bodies. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report on the consortium on DLB International Workshop. Neurology 47 (1996) 1113-1124
50. Tohgi T., Takahashi S., and Abe T. The effect of age on concentration of monoamines, amino acids and their related substances in the cerebrospinal fluid. J. Neural Trans. 5 (1993) 215-226
51. Uchihara T., Tsuchiya K., and Kosaka K. Selective loss of nigral neurons in Pick's disease: a morphometric study. Acta Neuropathol. 81 (1990) 155-161
52. Yang Y., and Schmitt H.P. Frontotemporal dementia: evidence for impairment of ascending serotonergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method. Acta Neuropathol. 101 (2001) 256-270